VA to offer new ketamine-based nasal spray to help combat depression

news

Editor's Note: This article by Patricia Kime originally appeared on Military.com, a leading source of news for the military and veteran community.

The newest FDA-approved medication to treat severe depression, a nasal spray based on the anesthetic (and misused hallucinogenic party drug) ketamine, will soon be available to veterans treated within the Department of Veterans Affairs.


In a move that may help thousands of former service members with depression that has not improved with other treatments, VA officials announced Tuesday that the department's doctors are now authorized to prescribe Spravato, the brand name for esketamine, a molecular variation of ketamine.

The decision to offer a drug hailed by many as a breakthrough in treatment for its speedy results -- often relieving symptoms in hours and days, not weeks -- shows the VA's "commitment to seek new ways to provide the best health care available for our nation's veterans," Secretary Robert Wilkie said in a release.

"We're pleased to be able to expand options for Veterans with depression who have not responded to other treatments," Wilkie added.

The treatment will be available to veterans based on a physician's assessment and only will be administered to patients who have tried at least two antidepressant medications and continue to have symptoms of major depressive disorder.

An estimated 16 million Americans have had at least one major episode of depression, and of those, 1 in 3 are considered treatment-resistant. In the veteran population of 20 million, the estimated diagnosis rate of depression is 14 percent -- up to 2.8 million veterans. Between one-third and half of those veterans may be treatment-resistant.

The lack of effective medications for difficult-to-treat patients prompted the Food and Drug Administration to place esketamine on a fast track, expediting its review of the drug to ensure that it went to patent as soon as safely possible, according to administration officials.

"Controlled clinical trials that studied the safety and efficacy of this drug, along with careful review through the FDA's drug approval process, including a robust discussion with our external advisory committees, were important in our decision to approve this treatment," said Dr. Tiffany Farchione, acting director of the FDA's Center for Drug Evaluation and Research Division of Psychiatry Products, in a release.

As with any other medication, there are risks. Spravato carries a boxed warning for side effects that include misuse, the reason it is administered under a doctor's supervision. The list of side effects includes sedation and blood pressure spikes and disassociation, such as feelings of physical paralysis and out-of-body experiences. It also can cause suicidal thoughts and behaviors.

Acknowledging the dangers, FDA made esketamine available only through a restricted distribution system.

A veteran prescribed Spravato would inhale the nasal spray at a medical facility while under supervision of a medical provider, and would be monitored for at least two hours after receiving the dose. A typical prescription includes twice-weekly doses the first month, followed by a single dose weekly or biweekly as needed. Spravato cannot be dispensed for home use.

Spravato is made by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson. It is the first major antidepressant medication to hit the market in 30 years.

This article originally appeared on Military.com

More articles from Military.com:

SEE ALSO: The VA Is Eyeing Ketamine As An Emergency Treatment For Patients At High Suicide Risk

On Nov, 10, 2004, Army Staff Sgt. David Bellavia knew that he stood a good chance of dying as he tried to save his squad.

Bellavia survived the intense enemy fire and went on to single-handedly kill five insurgents as he cleared a three-story house in Fallujah during the iconic battle for the city. For his bravery that day, President Trump will present Bellavia with the Medal of Honor on Tuesday, making him the first living Iraq war veteran to receive the award.

In an interview with Task & Purpose, Bellavia recalled that the house where he fought insurgents was dark and filled with putrid water that flowed from broken pipes. The battle itself was an assault on his senses: The stench from the water, the darkness inside the home, and the sounds of footsteps that seemed to envelope him.

Read More Show Less
(U.S. Army/Pvt. Stephen Peters)

With the Imperial Japanese Army hot on his heels, Oscar Leonard says he barely slipped away from getting caught in the grueling Bataan Death March in 1942 by jumping into a choppy bay in the dark of the night, clinging to a log and paddling to the Allied-fortified island of Corregidor.

After many weeks of fighting there and at Mindanao, he was finally captured by the Japanese and spent the next several years languishing under brutal conditions in Filipino and Japanese World War II POW camps.

Now, having just turned 100 years old, the Antioch resident has been recognized for his 42-month ordeal as a prisoner of war, thanks to the efforts of his friends at the Brentwood VFW Post #10789 and Congressman Jerry McNerney.

McNerney, Brentwood VFW Commander Steve Todd and Junior Vice Commander John Bradley helped obtain a POW award after doing research and requesting records to surprise Leonard during a birthday party last month.

Read More Show Less
(U.S. Marine Corps/Staff Sgt. Andrew Ochoa)

Editor's Note: This article by Gina Harkins originally appeared on Military.com, a leading source of news for the military and veteran community.

Hundreds of Marines will join their British counterparts at a massive urban training center this summer that will test the leathernecks' ability to fight a tech-savvy enemy in a crowded city filled with innocent civilians.

The North Carolina-based Kilo Company, 3rd Battalion, 8th Marines, will test drones, robots and other high-tech equipment at Muscatatuck Urban Training Center near Butlerville, Indiana, in August.

They'll spend weeks weaving through underground tunnels and simulating fires in a mock packed downtown city center. They'll also face off against their peers, who will be equipped with off-the-shelf drones and other gadgets the enemy is now easily able to bring to the fight.

It's the start of a four-year effort, known as Project Metropolis, that leaders say will transform the way Marines train for urban battles. The effort is being led by the Marine Corps Warfighting Laboratory, based in Quantico, Virginia. It comes after service leaders identified a troubling problem following nearly two decades of war in the Middle East: adversaries have been studying their tactics and weaknesses, and now they know how to exploit them.

Read More Show Less
(Reuters/Carlos Barria)

WASHINGTON/RIYADH (Reuters) - President Donald Trump imposed new U.S. sanctions onIran on Monday following Tehran's downing of an unmanned American drone and said the measures would target Iranian Supreme Leader Ayatollah Ali Khamenei.

Trump told reporters he was signing an executive order for the sanctions amid tensions between the United States and Iran that have grown since May, when Washington ordered all countries to halt imports of Iranian oil.

Trump also said the sanctions would have been imposed regardless of the incident over the drone. He said the supreme leaders was ultimately responsible for what Trump called "the hostile conduct of the regime."

"Sanctions imposed through the executive order ... will deny the Supreme Leader and the Supreme Leader's office, and those closely affiliated with him and the office, access to key financial resources and support," Trump said.

Read More Show Less